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Abstract 
Metabolic disorders such as type two diabetes mellitus (T2DM) and obesity are known to have a chronic low 
grade inflammatory tissue environment as well as an increase in excess lipids. Current research suggests that 
a tightly regulated oligoprotein complex known as the NLRP3 inflammasome is highly activated in T2DM 
and obesity. However, it is not well understood the interplay between excess lipids, which was previously 
shown in our lab to cause lysosome damage, and inflammation. A key transcription factor that is known to 
have both an inflammatory effect as well as an effect on lipid metabolism is PPARγ. For this reason, we 
attempted to determine if PPARγ had an effect on the degree of pro-inflammatory cytokine release such as 
IL-1β in the presence of excess lipids. A myeloid specific knock-out of PPARγ (mPPARγ KO) showed 
significantly less IL-1β and IL-1α levels when stimulated with palmitate-LPS. The selective suppression of 
the IL-1 family occurred via transcriptional changes. RNA sequencing data showed that the mPPARγ KO 
had a heightened type 1 IFN signature, with both increases in IFNβ and IFN-regulated genes. The type-1 
interferon receptor antibody (IFNAR1 ab) raised IL-1 levels to wild type levels, confirming the PPARγ 
phenotype was due to the heightened IFNβ levels. When WT macrophages were stimulated with palm-LPS 
and recombinant IFNβ (rIFNβ), it phenocopied the mPPARγ KO macrophages, confirming IFNβ was 
sufficient to decrease IL-1 levels. These findings suggest crosstalk between lipid metabolism and 
inflammation in macrophages, adding to the understanding of the complex pathology seen in T2DM and 
obesity. 
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Introduction 
 
Type two diabetes mellitus (T2DM) is a chronic metabolic disorder that has become 
increasingly common in the United States and 
around the world. According to the American 
Diabetes Association, in 2015 almost 10% of the 
American population had T2DM which is 30.3 
million Americans (1). Since 1953, the CDC 
reports over a fivefold increase in the number of 
individuals with diabetes, as seen in the Figure 
on the right (2). As the prevalence of T2DM and 
obesity, which is also a chronic metabolic 
disorder often associated with T2DM, continue 
to skyrocket health care costs to manage these 
difficult diseases continue to increase accordingly. Diabetes is the seventh leading cause of death 
among Americans and is likely higher due to many diabetes complications related deaths.  
The hallmark of T2DM is insulin resistance, which is often monitored clinically with 
hemoglobin A1c (HbA1c) levels. However, blood glucose levels are not the only clinically relevant 
pathology associated with T2DM. Typically, T2DM presents with an excess in circulating free fatty 
acids (FFAs) and triglycerides, as well as excess lipid accumulation in tissues (3, 4). It is known 
that T2DM also has metabolic and inflammatory phenotypes which adds to the complexity of the 
disease. The immune system is known to be altered in the adipose tissue of patients with T2DM, 
as well in other tissues such as the liver (5). Despite the knowledge that both metabolism and 
inflammation play a key role in the pathology of T2DM, their interplay is not well understood. 
Therefore, it is advantageous for this reason to study the metabolic and inflammatory differences 
that are seen in patients with T2DM, to determine possible treatments.  
Specifically within T2DM, there are changes in lipid update and metabolism which can 
lead to the metabolic and inflammatory phenotypes seen. A high lipid environment causes an 
increase in lipid update from macrophages which can lead to a pro-inflammatory phenotype (6, 7). 
It is this low grade, but persistent inflammation that are related to the many complications of 
diabetes. When excess lipid is taken up by macrophages in conjunction with another stress signal, 
such as tissue damage from a pathogen or ischemia, the macrophage can be propelled into activation 
of an inflammatory response. This other stress signal needed can come in a variety of flavors such 
as lipopolysaccharide (LPS), silica, viral infection, double stranded DNA (dsNDA) and cholesterol 
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signals. It is when both excess lipid is present, as well as the other stress signal that an oligoprotein 
complex known as the NLRP3 inflammasome can become activated (8). The inflammasome is a 
tightly regulated inflammatory complex which leads to a pro-inflammatory phenotype due to 
release of certain cytokines (9, 10). The schematic below shows this concept.  
 
 The inflammasome activation will cause an inflammatory response, which has read outs of 
cytokine release, such as interluken-1 (IL-1) and tumor necrosis factor alpha (TNFα). The pro-
inflammatory cytokine IL-1β specifically is a hallmark cytokine secreted when the inflammasome 
is fully activated. IL-1 levels have been shown to be strongly associated with risk of T2DM and 
atherosclerosis in both animal and human models (11-14). Since the NLRP3 inflammasome 
requires two signals, namely signal 1 which is propagated through TLRs, and signal 2 which is 
from excess fatty acids leading to lysosome damage (8, 15). TLRs are critical innate immune 
receptors that respond to pathogens or tissue damage which provides the first priming signal for 
the inflammasome complex. The excess lipid environment was shown in our lab to lead to lysosome 
damage, which activates signal 2, leading to the fully formed and activated inflammasome (6). It 
is important to note that one signal is not sufficient to activate the complex, but when both danger 
signals are present, the inflammasome can become active.  
 Since it is known that both the high lipid environment and lysosome damage through signal 
2 are needed for the inflammasome complex to be active, we 
wanted to establish a mode which would mimic the T2DM 
environment and lead to activation of both signals. Palmitate, 
which is an 18-carbon chain fatty acid that is high concentrations 
in patients with T2DM was the source of signal 2 leading to 
lysosome damage (5, 6, 16).  LPS, which is an endotoxin, was 
given as the source of signal 1 leading to TLR4 activation. Signal 
1 is mediated through activation of a toll-like receptor (TLR), 
which is an innate immune receptor on the cell surface, by a 
ligand (17, 18). This leads to activation of NF-κB and 
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upregulation of transcripts such as NLRP3 and pro-IL-1β. The second signal, in our lab the 
palmitate, stimulates the assembly of the inflammasome complex, and allows for caspase-1 to 
cleave pro-IL-1β (18, 19). This allow for the release of mature IL-1β which is biologically active 
and can lead to pro-inflammatory effects. Without both signals mature IL-1β cannot be released (5, 
17). Since the different signals lead to distinct activation of different parts of the inflammasome 
complex, that can be used as markers to determine what changes are arising from different 
treatments or cell lines.   
It was of interest to our lab to better understand the mechanism by which a high lipid 
environment can lead to excess inflammation in macrophages and determine the interplay between 
inflammation and metabolism, since these are hallmark pathologies associate with T2DM. For this 
reason, a transcription factor called peroxisome proliferator-activated receptors-gamma (PPARγ) 
became of interest to us. PPARγ is in a class of nuclear receptors and is expressed in immune cells 
such as primary macrophages (20). PPARγ is known to affect lipid modulation and it aids in fatty 
acid update which was established earlier in this paper to lead to inflammasome activation (18, 21). 
Current research supports that PPARγ has largely an anti-inflammatory role, since activation of 
PPARγ leads to down-regulation of pro-inflammatory cytokines such as iNOS and TNF-α (20). 
Agonists of PPARγ are currently used therapeutically for patients with T2DM, due to data that 
showed loss of PPARγ from obesity models of macrophages led to increased insulin resistance (22, 
23). However, agonists of PPARγ use in humans is controversial due to cardiovascular 
complications.  
Based on this prior data, we hypothesized that PPARγ would suppress inflammasome 
activation, and understanding its mechanism of action could provide insight into the interplay 
between lipid metabolism and inflammation in macrophages. Therefore, we also hypothesized that 
loss of PPARγ from primary macrophages would heighten inflammasome activity and increase 
pro-inflammatory cytokines synthesis and release. This study investigated a myeloid specific 
knock-out of PPARγ mouse model (mPPARγ KO) to test this hypothesis. Interestingly, we found 
that loss of PPARγ from myeloid cells stimulated with palmitate and LPS to activate the NLRP3 
inflammasome led to selective decrease in IL-1β and IL-1α release. This selective decrease in IL-
1 levels occurred due to mRNA regulation which led to decrease in the production of pro-IL-1β 
and pro-IL-1α protein. RNA sequencing showed a heightening type 1 interferon (IFN) response via 
upregulation of type 1 IFN genes in the stimulated mPPARγ KO macrophages. IFNβ, a type 1 IFN 
cytokine, was both necessary and sufficient to lead to the selective reduction in IL-1 levels in 
stimulated cells. Our lab confirmed these finding via qPCR analyzing mRNA levels of IFNβ 
regulated genes. When IFNβ signaling was blocked by the addition of the type 1 interferon receptor 
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(IFNAR1) antibody, IL-1 levels were normalized to wild type (WT) levels. Furthermore, when WT 
macrophages were treated with recombinant IFNβ (rIFNβ), it led to selective reduction in IL-1 
levels, phenocopying the mPPARγ KO cells. When a synthetic ligand of PPARγ, rosiglitazone, was 
given it lead to suppression of IFNβ and IFN-regulated genes. A prior study showed similar results 
that activation of PPARγ led to negative regulation of IFNβ production (20). This data suggests 
that loss of PPARγ from primary macrophages leads to heightened IFNβ production, which leads 
to suppression of the transcription of IL-1 levels. It is important to know that this data is currently 
part of a larger project in which the manuscript is currently under review to be published in the 
Journal of Immunology (24).   
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Methods 
Reagents- L-NIL was from Enzo life sciences (Farmingdale, NY, USA). T0070907 was from 
TOCRIS (Minneapolis, MN, USA). Rosiglitazone and α-tubulin antibody were from Sigma 
Chemical (St. Louis, MO, USA). IL-1β, IL-1α,  NLRP3, STAT1 and phospho-STAT1(#14994) 
antibodies were from Cell Signaling (Danvers, MA, USA). IFNβ and the IFNβ ELISA were from 
PBL (Piscataway, NJ, USA). The PE conjugated α-IFNAR antibody were from Biolegend (San 
Diego, CA, USA). IFNAR blocking antibody (MAR1-5AE) and control IgG were from Leinco 
Technologies (St. Louis, MO, USA).  Duoset ELISA kits (IL-1β, IL-1α, TNFα) were from R&D 
Systems (Minneapolis, MN, USA). Ultrapure E. coli LPS and silica were from Invivogen (San 
Diego, CA, USA). Thioglycollate was from Difco-BD (Franklin Lakes, NJ, USA). Fatty acids were 
from Nu-Chek Prep (Waterville, MN, USA). Ultrapure-bovine serum albumin (BSA) was from 
Lampire (Ottsville, PA, USA) and was tested for TLR ligand contamination prior to use by treating 
primary macrophages and assaying for TNFα release. Full list of reagents used for the manuscript 
available (manuscript in preparation) (24).  
 
Cell Culture- Peritoneal macrophages (pMACs) are resident macrophages that are recruited in 
response to intraperitoneal injection of 3.58% sterile thioglycollate. Macrophages were isolated 
from C57BL/6, or the indicated knockout mice. Four days after injection the pMACs are then 
isolated using an 18 gauge needle. Cells were plated at a density of 1.0 X 106 cells/mL in 
Dulbecco’s modified Eagle’s medium containing 10% inactive fetal serum (IFS), 2mM L-
glutamine, 50 U/mL penicillin G sodium, 50U/mL streptomycin sulfate (pen-strep), and 1mM 
sodium pyruvate. When indicated medium was supplemented with 500 μM palmitate. Fatty acid 
supplemented medium was prepared by modification of the method of Spector. Briefly, a 20 mM 
solution of fatty acid in 0.01 M NaOH was incubated at 70 °C for 30 min. Dropwise addition of 1 
N NaOH facilitated solubilization of the fatty acid. Fatty acid soaps were complexed with 5% fatty 
acid-free BSA in phosphate-buffered saline at an 8:1 fatty acid to BSA molar ratio. The complexed 
fatty acid was added to the serum-containing cell culture medium to achieve a fatty acid 
concentration of 500 μM. The final fatty acid concentration in the medium was measured using a 
semimicroanalysis kit (Wako Chemicals). The final BSA concentration was measured using the 
Albumin Reagent (BCG, Sigma). The pH of the medium did not differ significantly with the 
addition of complexed fatty acid. This growth medium protocol was first described according to 
Ory and Schaffer lab (16). Stimulation of cells with palmitate and LPS were performed on the day 
after harvest. Peritoneal cells were plated on low adherence plates (Greiner Bio-One) for flow 
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cytometry experiments. Peritoneal cells were plated on a high adherence plate for RNA and protein 
experiments (Falcon). Cells used for flow cytometry were washed and removed from the plate with 
PBS, then 10 minutes with Cell Stripper (Gibco) and then 10 minutes with EDTA/trypsin (Sigma). 
Cells used for RT-qPCR were washed and removed from the plate with PBS on ice, then RNase 
free lysate buffer. Cells used for western blot were washed and removed from the plate with PBS 
on ice, then protease buffer was added and cells were gently scraped.  BSA-supplemented medium 
was used as a control. For cell stimulations, PBS or LPS (100 ng/mL) were added to BSA or 
palmitate-containing medium. For triggering the NLRP3 inflammasome by non-lipid activators 
pMACs were treated with LPS 100 ng/ml for 16h after which they were incubated with vehicle, 
rIFNβ, or rosiglitazone.  
 
Stimulations- There were four main types of stimulation performed during the experiments in this 
lab. To mimic the pro-inflammatory and excess lipid environment, the PL condition was used of 
palmitate and LPS (100ng/mL). The other treatments served as a control to compare when only 
signal 1 or 2 are given. PP condition contains the palmitate signal but uses PBS as a control to LPS. 
The BL conditions contain the LPS signal, but BSA is used as a control to palmitate. Finally, the 
BP condition contains both controls, namely BSA and PBS. It is important to note that only the PL 
condition contains both signals necessary to activate the inflammasome fully. After pMACs were 
allowed to adhere to the plate for 24 hours, the stimulation medial was made and added to cells. 
Stimulation media was left on cells for 22+ hours for ELISA, 8-16hrs for RNA, or 4-16hrs for 
protein.  
 
Interferon Receptor Antibody with Stimulations- Peritoneal macrophages were isolated and 
stimulated with BSA-PBS or palmitate-LPS according to protocol above. Cells were pre-stimulated 
with IFNAR1 antibody in DMEM for 24hrs in concentration. Then IFNAR1 antibody was added 
to PL media, or the same volume of vehicle to serve as a control for 8 hours. Cells were then washed 
with PBS, then ice cold lysis buffer was added.  
 
Recombinant IFN with Stimulations- Peritoneal macrophages were isolated and stimulated with 
BSA-PBS or palmitate-LPS according to protocol above. Cells were pre-stimulated with rIFNβ in 
DMEM overnight (~16hrs) in desired concentrations (either 25units, 50U, or 100U) or vehicle for 
control. Then the desired concentration of rIFNβ was added to PL media, or the same volume of 
vehicle to serve as a control for 1hr. Cells were then washed with PBS, then ice cold lysis buffer 
was added.  
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Rosiglitazone with Stimulations- Peritoneal macrophages were isolated and stimulated with BSA-
PBS or palmitate-LPS according to protocol above. Cells were pre-stimulated with rosiglitazone at 
desired concentration (either 1μΜ or 10μΜ) in DMEM or vehicle as control overnight (~16hrs). 
Then macrophages were treated with PL media with the desired concentration of rosiglitazone or 
the same volume of vehicle to serve as a control for 8 hours. Cells were then washed with PBS, 
then ice cold lysis buffer was added.  
 
Mice- Wild type (WT) C57BL/6 mice were bred in our mouse facility at Washington University 
School of Medicine. PPARγflox x LysM-Cre mice and LysM-Cre control mice were from Gwen 
Randolph (Washington University) and bred in our facility; IFNR1flox x LysM-Cre were from 
Mike Diamond (Washington University). All lines were in the C57BL/6 background. Mice were 
maintained in a pathogen-free facility on a standard chow diet ad libitum (6% fat). All animal 
experiments were conducted in strict accordance with National Institutes of Health guidelines for 
humane treatment of animals and were reviewed by the Animal Studies Committee of Washington 
University School of Medicine.  
 
LysM-Cre Knock-out- The myeloid specific PPARγ knock-out (mPPARγ KO) was created using a 
LysM-Cre technology. This allowed us to selectively deplete PPARγ sequence from myeloid cells. 
Cre is the DNA recombinase that binds to the LoxP sequence. LoxP sequence was inserted in 
myeloid cells flanking each side of the PPARγ gene. LysM allows for the expression of Cre, making 
it macrophage specific. The Cre binds to the LoxP promoters, flanking the PPARγ gene, and causes 
the removal of the PPARγ sequence.  
 
RNA Isolation, Quantitative RT-PCR and RNA sequencing-  Total cellular RNA was isolated using 
Qiagen RNeasy column and reverse-transcribed using a high capacity cDNA reverse transcription 
kit (Applied Biosystems). Real-time qRT-PCR was performed using SYBR green reagent (Applied 
Biosystems) on an ABI 7500 Fast thermocycler. Relative gene expression was determined using 
Δ-Δ CT method normalized to 36B4 expression. Mouse primers sequence were as follows (all are 
5’ to 3’): 36B4 (forward, ATC CCT GAC CCG CCG TGA, reverse TGG GAG TAG ACA CAA 
GGT ACA ACC C); IL-1β (forward, AGG GAG AAC CAA GCA ACG ACA AAA; reverse, TGG 
GGA ACT CTG CAG ACT CAA ACT); NLRP3 (forward; AAA ATG CCT TGG GAG ACT CA; 
reverse AAG TAA GGC CGG AAT TCA CC; CXCL10 (forward; ATC ATC CCT GCG AGC 
CTA TCC TG; reverse, CGG ATT CAG ACA TCT CTG CTC ATC). TNFα (forward, 5′-CAT 
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CTT CTC AAA ATT CGA GTG ACA A-3′, reverse, 5′-TGG GAG TAG ACA CAA GGT ACA 
ACC C-3′); IFNβ (forward, 5′-GAC GGA GAA GAT GCA GAA GAG TT-3′, reverse, 5′-AGT 
TCA TCC AGG AGA CGT ACA AC-3′); IL-1α (forward- TGA GTT TTG GTG TTT CTG GC, 
reverse- TCG GGA GGA GAC GAC TCT AA); iNOS (forward- ACA TCG ACC CGT CCA CAG 
TAT, reverse- CAG AGG GGT AGG CTT GTC TC); MX1 (forward- CCA GGT CCT GCT CCA 
CAC, reverse- TCT GAG GAG AGC CAG ACG AT).  
The total cellular RNA was also prepared for RNA sequencing with the Clonetech SMARTer kit 
according to manufacturer’s protocols, ligated with adapters and unique molecular indexes for each 
sample for every read, and then sequenced on one single-end 50bp lane on an Illumina HiSeq 3000. 
Full information on RNA-seq data available in manuscript (24).  
 
Western Blotting- Total cellular protein was isolated by lysing cells in 150 mM NaCl, 10mM Tris 
(pH 8), Triton X-100 1% and 1 X Complete protease inhibitor (Thermo-Fisher Scientific). Proteins 
were separated on a TGX gradient gel (4-12%, Bio-Rad) for approximately 30 minutes. Proteins 
were then transferred from the gel  to a nitrocellulose membrane. Protein was transferred overnight 
at 4 degrees C with constant amps. Western blotting for pro-IL-1β and tubulin was performed using 
40μg of total cellular protein. The indicated primary antibody was diluted to desired concentration 
in milk in PBS and allowed to sit overnight at 4 degrees C. The next morning indicated secondary 
antibody was diluted to desired concentration in reagent diluent (1% BSA in PBS) was allowed to 
sit for 2+ hours at room temperature. Strips were washed between antibodies with PBS. Strips were 
developed with developing solutions per manufactures instructions and read in a BioRad machine. 
Tubulin was used a loading control.  
 
IL-1β ELISA- Supernatants were harvested from macrophage culture after 24 hr stimulations. IL-
1β, IL-1α and TNFα were quantified using a DuoSet ELISA kit (R&D Systems) according to 
manufacturer’s instructions. A 96 well plate was coated overnight at room temperature with 100μL 
capture antibody with an analyte-specific antibody. The next morning the plate was washed with 
wash buffer (3x in PBS + 1% Tween). Then blocking buffer (reagent diluent, 1% BSA in PBS 
filtered) was allowed to sit on the plate for 2+ hrs in room temperature. The plate was then washed 
with wash buffer. Supernatants samples were diluted 1:2 in DMEM and a standard curve was then 
plated. Standard curve samples were created with a standard recombinant analyte in a 7 point 
standard curve using 2-fold serial dilutions in DMEM. Standard curve ranged from 1000 pg/mL to 
15.6 pg/mL, and just DMEM served at the 8th standard curve point of 0 pg/mL so that any trace 
fluoresce from the DMEM was accounted for. Samples were allowed to incubate at room 
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temperature for 2+ hours. The plate was then washed with wash buffer. The plate was then coated 
in 100μL detection antibody for 2+ hrs. The plate was then washed with wash buffer. 100μL of 
working dilution of Streptavidin-HRP was then added to each well for 20 minutes in the dark at 
room temperature. 100μL of Substrate solution was then added to each well and allowed to incubate 
at room temperature in the dark for 20 minutes. 50μL of Stop Solution was then added to each well 
and gently mixed. The plate was then analyzed immediately for its optical density in a microplate 
reader set to 450 nm with a wavelength correction of 540nm to 570nm. Sample concentrations were 
compared to standard curve to determine optical density level. All antibodies were diluted from 
stock concentrations in reagent diluent (1% BSA in PBS filtered).  
 
IFNR1 Flow Cytometry- Peritoneal macrophages were removed from low adherence plate and 1 x 
106 cells were pelleted in FACS buffer (PBS, 1%BSA) and incubated with Fc block x 5 min on ice 
followed by incubation with IFNR1-PE (1:200) for 30 minutes on ice in the dark.  Samples were 
analyzed on a FACS caliber flow cytometer (BD). 
 
LDH Release Assay- After stimulations, macrophage supernatants were collected at 24 hrs, LDH 
was quantified using the CytoTox 96 non-radioactive cytotoxicity assay (Promega) per the 
manufacturer’s instructions using a Tecan Infinite M200 per reader. Total LDH content was 
determined using the lysis buffer provided by the manufacturer. Prior studies in our lab 
(unpublished data) has shown there is no significant differences in LDH levels between WT and 
KO cells, indicating KO cells are not dying at a fast rate than WT cells.   
 
IFNR1 Flow Cytometry- After the indicated stimulations, pMACs were removed from the low 
adherence plates as described above. 1 X 106 cells were pelleted in PBS and 1%BSA (FACS buffer) 
and incubated with Fc block for 5 minutes on ice followed by incubation with IFNR-PE (1:200) 
for 30 minutes on ice in the dark. Samples were analyzed on a FACS caliber flow cytometer (BD).   
 
Statistics- Statistical analysis was performed using GraphPad Prism software. All the results are 
expressed as means ± S.E. Groups were prepared by paired Student’s t-test or two way analysis of 
variance as appropriate. A value of p ≤ 0.05 was considered significant.  
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Results 
Myeloid Specific PPARγ Knock-out Mice Show Decreased IL-1 Levels 
To gain a better understanding about what PPARγ was doing in macrophages, our lab 
created a myeloid specific PPARγ knock-out mouse. The hope of this model was to determine how 
lipid metabolism regulates inflammasome activation. First, we wanted to establish that in fact our 
mode was a myeloid specific knock-out. Figure 1A shows a western blot of our knock-out mouse, 
determining that in fact it was a true knock-out. The knock-out was also previously established in 
prior work in our lab (8, 25).  
 Peritoneal macrophages were elicited from WT and mPPARγ KO mice to study how they 
responded to the T2DM mimicked environment. The cells were bathed in palmitate or stearate and 
LPS for 8 hours or with BSA and vehicle. The stimulation protocol showed a significant decrease 
in IL-1β levels in the mPPARγ KO mice as compared with WT mice (Figure 1 B). Similarly, there 
was a reduction in the IL-1α , another pro-inflammatory cytokine of the IL-1 family (Figure 1C). 
This was shown to be selective for IL-1β, since TNFα was unchanged, and trended higher in the 
mPPARγ KO mice (Figure 1D). The unchanged TNFα levels indicates that knocking out PPARγ 
did not cause a global inflammasome defect or derangement of the innate immune receptor needed 
to signal inflammasome activation. This was also shown in our lab to be true in-vivo (data not 
shown). WT and mPPARγ KO mice were injected with LPS, then IL-1β, TNFα, IL-1α were 
measured in the peritoneal fluid 16 hours post LPS injection. 
 
Figure 1 
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Figure 1. Myeloid Specific PPARγ Knock-out Mice Show Decreased IL-1 Levels. (A) Protein 
from peritoneal macrophages (pMACs) isolated from WT or mPPARγ KO mice were analyzed via 
western blot. (B-D) pMACs isolated from WT (open bars) or mPPARγKO mice (filled bars) were 
treated with vehicle (BSA-LPS), palm (250 µM)-LPS (100 ng), or stearate (150 µM)-LPS for 20hrs 
and the release of IL-1β (B), (C) IL-1α, and (D) TNFα was determined by ELISA. 
 
IL-1 Levels Decrease Due to Signal 1 Effect on the Inflammasome  
Once we determined that there was a specific inhibition of IL-1 levels when mPPARγ KO 
cells were treated with PL, we wanted to determine what part of the inflammasome complex was 
being effected. More specifically, we wanted to determine if the effect was specifically on IL-1β 
transcription, translation, or release, or if it was due to something upstream in the inflammasome 
such as an effect on NLRP3. The inflammasome complex must receive both signal 1 and signal 2 
to have release of the mature IL-1β. Pro-IL-1β is a product of signal 1 activation and is necessary 
to get mature IL-1β cleavage from caspase-1 (26). At the protein level, there was also shown to be 
a difference in pro-IL-1β or pro-IL-1α (Figure 2A). When examining NLRP3, there were no 
differences at the mRNA level, but instead was selectively decreasing IL-1β and IL-1α mRNA 
(Figure 2B). This data suggests that all of the necessary machinery is present within these KO cells, 
there is just a selective inhibition of IL-1. Since the pro-IL-1 protein is affected, this indicates that 
PPARγ deficiency is causing a transcriptional change in the signal 1 effect on the inflammasome 
leading to the decreased IL-1 levels seen in our KO model. When a kinetic analysis of pMACs in 
PL from 0-16 hrs was performed, there was proportional reduction in IL-1β mRNA levels (Figure 
2C). When TNFα mRNA was measured, there was no difference between the genotypes (Figure 
2D).  
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Figure 2 
 
Figure 2. IL-1 Levels Decrease Due to Signal 1 Effect on the Inflammasome. (A) WT or 
mPPARγKO (KO) macrophages were stimulated with BSA-PBS (vehicle) or palm-LPS for 16hrs 
and the protein level of pro-IL-1β and pro-IL-1α was assessed by western blotting.  Tubulin (tub) 
is shown as a loading control. (B) pMACs isolated from WT (open bars) or mPPARγKO mice 
(filled bars) were treated with vehicle or palm-LPS for 8hrs and mRNA expression of IL-1β, IL-
1α, and NLRP3 was assessed by qRT-PCR. (C, D) Kinetic assessment of IL-1β (C) and TNFα (D) 
mRNA levels following palm-LPS stimulation in WT and mPPARγKO cells. Bar graphs report the 
mean ± standard error (SE) for a minimum of 3 experiments, each performed in triplicate. *, p<0.05 
for WT vs. mPPARγKO or; ns, non-significant.  
 
RNA Sequencing of Myeloid Specific PPARγ Knock-out Mice Reveals Enhanced IFNβ Pathways  
Since PPARγ is a transcription factor, next we wanted to perform RNA sequencing on the 
cells since RNA sequencing is an unbiased quantitative method to determine all the transcripts 
present within a cell. The RNA sequencing data was useful for us to determine if any biological 
pathways of relevance in the WT versus the KO cells. Cells were treated under four different 
conditions: BSA and PBS (BP), BSA and LPS (BL), palmitate and LPS (PL) and palmitate and 
PBS (PP). Figure 3 compares the WT to the KO cells, highlighting the biggest differences between 
the two cell lines, with a cutoff of a 2.0-fold change in gene expression. The top 20 upregulated 
pathways in the mPPARγ KO versus the WT pMACs are show in Figure 3A. Interestingly, one of 
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the biggest readouts was differences in the IFNβ pathway. The boxed hits indicate pathways that 
are associated with the innate immune response and interferonβ (IFNβ). Figure 3B shows the top 
10 differences between the KO and WT cells for biological processes. Note that 6 of the top 10 are 
related to IFNβ production or response. Figure 3C is a heatmap representing differences in gene 
expression in the response to IFNβ module shows consistent increases in gene expression for IFNβ 
and IFN target genes in the KO cells. Blue indicates lower gene expression, whereas the red 
indicates higher gene expression. There is an increase in almost all of the IFNβ related genes in the 
KO cells compared with the WT mice under the PL treatment.  
 
Figure 3 
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Figure 3. RNA Sequencing of Myeloid Specific PPARγ Knock-out Mice Reveals Enhanced 
IFNβ Pathways. (A-C) WT or PPARγKO pMACs were treated with BSA-PBS or palm-LPS for 
8hrs after which RNA was isolated and RNA sequencing was performed.  (A) Pathway analysis of 
the top 20 upregulated biologic processes in PPARγKO compared to WT pMACs treated with 
palm-LPS.  Biologic pathways related to innate host defense are shown in the boxes. (B) Group 
summary for pathways related to IFNβ in PPARg vs. WT pMACS treated with LPS.  (C) Heatmap 
expression profile of genes from the cellular response to IFNβ GO biologic processes module. WT 
and PPARγKO cells are shown under basal conditions (BSA-PBS) and after activation (palm-LPS). 
 
Stimulated Myeloid Specific PPARγ Deficient Macrophages Have Heightened IFNβ Expression 
and Release  
To confirm this in our lab, we performed qPCR on the mPPARγ KO and WT pMACs 
analyzing type 1 interferon gene targets including MX1, and CXCL10. MX1 and CXCL10 are IFN-
regulated genes, so act as biomarkers to measure IFNβ activity (27). At the mRNA level, there was 
a significant increase in both IFN-regulated genes (Figure 4A). At the protein level, phoso-STAT1 
was then analyzed in the KO cells treated with PL when compared with the WT (Figure 4B). IFNβ, 
a type-1 interferon, signals through the type 1 interferon receptor (IFNAR1), which is known to 
lead to phosphorylation of STAT (28). STAT1 is a transcription factor which then can drive gene 
expression of IFN-dependent genes. Western blot showed an increase in STAT1 phosphorylation 
in the mPPARγ KO cells compared to the WT (Figure 4B). To note in Figure 4C, there is no 
differences in the interferon receptor density between the WT and KO cells, as analyzed via flow 
cytometry. This indicates that the differences seen in the IFN related genes and IFNβ levels is due 
to changes in transcription or release, and not due to an increase density in its receptor. We then 
analyzed IFNβ levels in the WT versus the KO cells at both an mRNA level and in cytokine release 
via ELISA. Figure 4D and E shows that the KO cells have about a 2 fold increase in the amount of 
IFNβ at both the mRNA and release level. This indicates that there is an increase in transcription 
of IFNβ as well as in the release of mature IFNβ. This data indicates that the mPPARγ KO cells 
have a heightened IFNβ response.  
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Figure 4 
 
Figure 4. Stimulated Myeloid Specific PPARγ Deficient Macrophages Have Heightened IFNβ 
Expression and Release. (A) pMACs isolated from WT (open bars) or mPPARγKO mice (filled 
bars) were treated with vehicle or palm-LPS for 8hrs and mRNA expression of MX1 and CXCL10 
targets was determined by qRT-PCR. (B) Macrophages were treated with vehicle or palm-LPS for 
4hrs or 8hrs after which cell lysates were isolated and phopho(P)-STAT1 (Y701) was assessed by 
western blotting. Total (tot) STAT1 and tubulin are shown as controls.  (C) pMACs from WT or 
PPARγ KO mice were stained with an antibody the type 1 interferon receptor (IFNAR) and receptor 
surface expression was assessed by flow cytometry and is shown as a representative histogram. (D) 
mRNA levels of IFNβ were quantified in WT and mPPARγKO cells at 1hr after palm-LPS 
treatment via qRT-PCR.  (D) IFNβ release from WT and KO pMACs 6hrs after palm-LPS 
stimulation via ELISA. Bar graphs report the mean ± standard error (SE) for a minimum of 3 
experiments, each performed in triplicate.  *, p<0.05 for WT vs. mPPARγKO; ns, non-significant 
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Neutralization of the IFNβ Signal Normalizes IL-1 Levels in Myeloid Specific PPARγ Knock-out 
Mice 
Next we wanted to determine if the heightened IFNβ response was a possible mechanism 
for the selective inhibition of IL-1 in the mPPARγ KO mice. To determine if IFNβ is necessary for 
the IL-1 response, we treated WT and the KO pMACs in the PL condition with a control IgG or 
the interferon receptor (IFNAR) antibody. IFNβ must go through the IFNAR1 receptor to enter into 
the pMACs and cause any cellular changes. The data showed that when the KO cells were treated 
with the IFNAR antibody returned the IL-1β levels to the WT baseline (Figure 5A). Note there was 
a decrease in the IL-1β levels when cells were treated with the control IgG, which is consistent with 
our previous data. It is also important to note that treatment with the IFNAR1 antibody led to a 
modest increase IL-1β levels in WT cells when compared with vehicle stimulation, which provides 
further evidence that IFNβ may be leading to the decreased IL-1 levels seen in the mPPARγ KO 
(Figure 5A). T0070907 is a known PPARγ antagonist. Cells were pre-stimulated with T0070907 
for 24hrs then stimulations were performed as specified in the methods. When T0070907 was given 
to WT cells it led to a decrease in IL-1β levels compared to WT cells treated with vehicle, which 
further confirmed that PPARγ was required for maximal IL-1 production and release (Figure 5B). 
When vehicle versus T0070907 was given to IFNR KO pMACs, IL-1β were the same between the 
two treatments (Figure 5B). IL-1β levels also increased compared to WT cells indicating that the 
reduction in IL-1β is dependent on the loss of PPARγ and augmented IFNβ. At the mRNA level, 
although the IL-1β levels in the KO cells have not completely normalized to WT levels, we see the 
trend that with the IFNAR antibody present, there is an increase in the IL-1β levels (Figure 5C). 
This is also seen to be selective since there is no significant difference in TNFα levels with the WT 
versus the KO cells both treated with the IFNAR antibody and the control IgG (Figure 5C). At the 
protein level there appears to be little to no difference in the amount of pro-IL-1β levels between 
the genotypes treated with the IFNAR antibody, and decreases in the amount of pro-IL-1β in the 
KO compared with the WT when the control IgG was given (Figure 5D). This appears to be 
selective for IL-1β since there are no differences in the NLRP3 protein with the treatments. Tubulin 
was used as a loading control.  
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Figure 5 
 
Figure 5. Neutralization of the IFNβ Signal Normalizes IL-1 Levels in Myeloid Specific 
PPARγ Knock-out Mice. (A) WT or PPARγKO pMACs were treated with palm-LPS for 20hrs in 
the presence of an IFNAR blocking antibody or control Ig and IL-1β release was quantified by 
ELISA. (B) WT or IFNAR KO pMACs were treated with veh or the PPARγ antagonist T0070907 
24hrs prior to stimulation with palm-LPS and IL-1β release was quantified by ELISA. (C, D) WT 
or PPARγKO pMACs were treated with palm-LPS for 8hrs (mRNA) or 16hrs (protein) in the 
presence of an IFNAR blocking antibody or control Ig and IL-1β expression was assessed via qRT-
PCR (C) and western blotting (D). Bar graphs report the mean ± standard error (SE) for a minimum 
of 3 experiments, each performed in triplicate.  *, p<0.05 for WT vs. mPPARγKO or; ns, non-
significant.  
 
Recombinant IFNβ Sufficient to Reproduce Myeloid Specific PPARγ Knock-out Phenotype  
After determining that neutralizing of the IFNβ response was necessary to normalize the 
IL-1β levels to the WT amount in the mPPARγ KO mice, we wanted to determine if IFNβ was 
sufficient to recapitulate the KO phenotype. Figure 6A shows that IL-1β release levels were 
decreased in a dose dependent manner when WT cells were treated with recombinant IFNβ (rIFNβ). 
TNFα, however, showed no difference in levels when rIFNβ was given exogenously (Figure 6B). 
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Obvious decreases in pro-IL-1β protein were also seen when rIFNβ was given as well (Figure 6C). 
Exogenous IFNβ given to WT cells also lead to a decrease in IL-1β mRNA (Figure 6D). Not 
surprisingly, treatment with rIFNβ also lead to increased CXCL10, which as previously stated is a 
known IFNβ regulated gene. When rIFNβ was given to WT cells treated with the IFNAR antibody, 
however, the IL-1β levels were normalized to WT cells not given exogenous IFNβ (Figure 6E). 
This data phenocopied what was previously seen in the mPPARγ KO cells, giving a strong 
indication that IFNβ is both necessary and sufficient to cause the phenotype seen.  
 
Figure 6 
 
Figure 6. Recombinant IFNβ Sufficient to Reproduce Myeloid Specific PPARγ Knock-out 
Phenotype. (A, B) WT pMACs were treated with palm-LPS and increasing concentrations of IFNβ 
after which IL-1β (A) and TNFα (B) release was quantified by ELISA. (C) Macrophages were 
treated with vehicle or palm-LPS for 16hrs in the presence of IFNβ (50U) and pro-IL-1β and 
NLRP3 protein levels were assessed by western blotting. Tubulin is shown as a loading control. 
(D) pMACS were treated as indicated and gene expression of IL-1β and CXCL10 was assessed 
8hrs after stimulation via qRT-PCR. (E) pMACS were stimulated with palm-LPS ± IFNβ in the 
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presence of IFNAR blocking ab or control Ig and IL-1β release was determined by ELISA. Bar 
graphs report the mean ± standard error (SE) for a minimum of 3 experiments, each performed in 
triplicate.  *, p<0.05 for veh vs. IFNβ or WT vs. IFNAR KO; ns, non-significant.  
 
Agonist of PPARγ Reverses Myeloid Specific PPARγ Knock-out Phenotype  
The lab also performed a gain of function model to determine how a heightened PPARγ 
signal would modulate inflammatory responses and lipid handling in pMACs. Rosiglitazone is a 
known agonist of PPARγ and a pharmacological agent given as an antidiabetic drug which works 
to increase insulin sensitivity by binding to PPAR and making cells more responsive to insulin (29). 
Two different doses of rosiglitazone were given, 1μM which would lead to PPARγ dependent 
effects, and 10μM which would produce PPARγ independent effects, and likely works to activate 
other transcription factors such as PPARβ/δ. The pMACs were incubated with 1μM of rosiglitazone 
for 16 hrs prior to the addition of vehicle or palm-LPS. Not surprisingly, there was an increase in 
IFNβ and IFN-regulated genes in the mPPARγ KO mice when compared to the WT (Figure 7A-
D). As mentioned previously, CXCL10 and MX1 are IFNβ regulated genes. iNOS is a specific 
isotype of the general enzyme class nitric oxide synthase involved in immune responses, which 
catalyzes the production of nitric oxide (NO). It is known that PPARγ negatively regulates the 
expression of iNOS  (30). Not surprisingly, iNOS mRNA decreased in a dose dependent manner 
when WT cells were treated with rosiglitazone. In the KO cells, there was no difference in iNOS 
mRNA when treated with the low dose rosiglitazone, but when the agonist led to PPARγ 
independent effects, there was also a reduction in iNOS mRNA (Figure 7D).  Figure 7A shows that 
when WT cells were treated with 1μM rosiglitazone, there was a reduction in the amount of IFNβ 
present, which is expected since it would augment the effects of PPARγ. As expected, IL-1β mRNA 
was down in the KO cells compared to WT (Figure 7E). Interestingly, however, the presence of 
rosiglitazone had little to no effect on IL-1β levels in WT cells (Figure 7E). TNFα expression was 
unaffected by both loss of PPARγ and augmentation of PPARβ/δ with the addition of rosiglitazone 
(Figure 7F). To note in all of the panels in Figure 7, there was no significant difference in the KO 
cells when treated with vehicle or 1μM of rosiglitazone, which is expected since PPARγ is absent 
from these cells. However, when cells were stimulated with 10μM of rosiglitazone, there began to 
be PPARγ independent effects as seen in Figure 7B-E. The higher dose of rosiglitazone was shown 
to suppress IFN-gene expression, and also restore IL-1β levels to baseline WT levels.  
 
  
P a g e  | 20 
 
Figure 7 
 
Figure 7. Agonist of PPARγ Reverses Myeloid Specific PPARγ Knock-out Phenotype. (A-F) 
WT or PPARγ KO macrophages were treated with BSA-PBS/veh (open bars), palm-LPS/veh (filled 
bars), palm-LPS/rosiglitazone 1 µM (dark gray bars) or LPS/rosiglitazone 10 µM (light gray bars) 
for 16hrs followed by stimulation with palm-LPS for 8hrs (or 1hr in the case of IFNβ) in continued 
presence of the PPARγ agonist. mRNA was isolated from the macrophages and the expression of 
IFNβ (A) and several of its gene targets (B-D) was assessed by qRT-PCR. In addition, mRNA 
expression of the pro-inflammatory cytokines IL-1β (E) and TNFα (F) was also determined.  Bar 
graphs report the mean ± standard error (SE) for a minimum of 3 experiments, each performed in 
triplicate.  *, p<0.05 for veh vs. rosiglitazone; ns, non-significant.  
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Discussion 
Along with insulin resistant, two hallmarks of T2DM are metabolic stress and 
inflammation. It has been previously established that metabolic changes that take place can lead to 
inflammasome activation due to changes in lipid stress and handling (29). A hallmark of T2DM 
and obesity is a lipid bathed environment which is known to lead to metabolic stress (6, 8, 31). As 
part of the innate immune system, macrophages play a critical role in regulation of tissue damage 
and inflammation. It is for this reason our lab studied pMACs to gain insight into the interplay 
between lipid handling and inflammation.  Our lab has previously shown that increased IL-1β is 
released from macrophages in a high lipid environment, as well as having a critical role in 
inflammation (6). Finding possible mechanisms of selective reduction of IL-1β would therefore be 
advantageous therapeutically to reduce the inflammatory response.  
In this study, pMACs were stimulated with palmitate and LPS acting as the two signals 
needed to activate the inflammasome. Palmitate mimics the high lipid environment known to be 
associated with T2DM and was shown in our lab to lead to lysosome damage (8). LPS acts as the 
other signal necessary to fully activate the inflammasome and lead to mature IL-1β release. Myeloid 
specific PPARγ KO pMACs were stimulated with PL showed selective inhibition of IL-1β, but not 
a global wipe out of the inflammasome, as noted with no changes in TNFα, which is another 
cytokine known to be released by activated macrophages. PPARγ is a transcription factor, but it is 
known that it does not directly affect IL-1β transcription by sitting on its promoter (32).  
Interestingly, the mPPARγ KO cells showed increased IFNβ both through RNA sequencing, and 
confirmed in our lab with mRNA data on IFN-regulated genes.  Furthermore, IFNβ was seen to be 
both necessary and sufficient to recapitulate the mPPARγ KO cell’s phenotype. This was shown 
by blocking IFNβ through the IFNR antibody, leading to loss of the mPPARγ KO phenotype of 
decreased IL-1β levels. When WT cells were stimulated and incubated with rIFNβ, there was a 
selective decrease in IL-1 levels, which is consistent with the mPPARγ KO phenotype. Opposite 
of the mPPARγ KO model, when we performed a gain of function of PPARγ by the addition of 
rosiglitazone, a synthetic PPARγ agonist, we saw a decreased IFNβ and IFN-regulated genes 
signature. This data taken together demonstrates that the augmented IFNβ response was responsible 
for the selective inhibition of IL-1 levels in macrophages deficient in PPARγ. These results add to 
the understanding of antagonistic relationship between PPARγ and IFN related inflammatory 
responses.   
Recently published in The New England Journal of Medicine, the CANTOS Trial Group 
conducted a clinical trial using an IL-1β blocking antibody. Results showed a 26 percent greater 
reduction in high-sensitivity C-reactive protein and a significantly lower rate of recurrent 
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cardiovascular events when compared with the placebo. This provides further evidence to the 
benefits of finding therapeutic agents to selectively inhibit IL-1β to reduce inflammation and 
metabolic stress. Currently, IFNβ is used as a therapeutically to reduce symptoms of multiple 
sclerosis (MS) even though it is somewhat unclear as to its mechanism of action. IFNβ is known to 
suppress T cell activation as well as regulation of pro and anti-inflammatory cytokines (33-36). 
Both of these treatments provide insight into possible clinically relevant treatments that could 
possibly come from the data presented in this thesis.  
Further investigations will be necessary to determine the mechanism behind which IFNβ 
is working to selectively inhibit IL-1β levels. Furthermore, it should be established how the loss of 
PPARγ leads to an increase of IFNβ. One attempt to determine the mechanism of interplay would 
be to create a PPARγ / IFNβ KO mouse model. Being able to mechanistically establish the 
connection between PPARγ and IFNβ, and IFNβ and IL-1 would aid in better understanding how 
to decreases the release of pro-inflammatory cytokines. Also, further research should investigate 
how agonists of PPARγ could be used therapeutically to suppress IFNβ production, which would 
be advantageous for patients suffering from autoimmune diseases, since type 1 IFN can promote 
autoimmunity (37, 38). 
In summary, the current study identifies that myeloid specific loss of the transcription 
factor PPARγ leads to selective reduction of IL-1β via increased IFNβ in peritoneal macrophages. 
Reduction in IL-1β is via a signal 1 change in the inflammasome complex, as seen by a reduction 
in pro-IL-1β without reduction in other known inflammasome markers including NLRP3 and 
TNFα. IFNβ was both necessary and sufficient to reduce IL-1β levels. Macrophage dysfunction is 
a key component to the pathology of T2DM and obesity. Understanding how the high lipid 
environment leads to metabolic stress and a pro-inflammatory state. Our data adds to the 
complexity between inflammation and lipid metabolism, which is known to be at play in prevalent 
metabolic diseases such as T2DM and obesity.  
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